کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
2875347 | 1573928 | 2012 | 12 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Statement Regarding the Pre and Post Market Assessment of Durable, Implantable Ventricular Assist Devices in the United States
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
FDAMCsBTCCMSHDENHLBIINTERMACSBTTPMA - LDC هاVentricular assist device - دستگاه کمک بطنیFood and Drug Administration - سازمان غذا و داروNational Heart, Lung, and Blood Institute - قلب ملی، ریه و موسسه خونCenters for Medicare and Medicaid Services - مراکز خدمات Medicare و Medicaidhumanitarian device exemption - معافیت دستگاه بشردوستانهdestination therapy - مقصد درمانMechanical circulatory support - پشتیبانی مکانیکی گردش خونbridge to transplant - پل به پیوندpremarket approval - پیش فروشVAD - چه
موضوعات مرتبط
علوم پزشکی و سلامت
پزشکی و دندانپزشکی
کاردیولوژی و پزشکی قلب و عروق
پیش نمایش صفحه اول مقاله
چکیده انگلیسی
The incorporation of complex medical device technologies into clinical practice is governed by critical oversight of the US Food and Drug Administration. This regulatory process requires a judicious balance between assuring safety and efficacy, while providing efficient review to facilitate access to innovative therapies. Recent contrasting views of the regulatory process have emphasized the difficulties in obtaining an optimal balance. Mechanical circulatory support has evolved to become an important therapy for patients who have advanced heart failure with the advent of more durable, implantable ventricular assist devices. The regulatory oversight of these new technologies has been difficult owing to the complexities of these devices, associated adverse event profile, and severity of illness of the intended patient population. Maintaining a regulatory environment to foster efficient introduction of safe and effective technologies is critical to the success of ventricular assist device therapy and the health of patients with advanced heart failure. Physicians representing key surgical and cardiology societies, and representatives from the Food and Drug Administration, National Heart Lung, and Blood Institute, Centers for Medicare and Medicaid Services, Interagency Registry of Mechanically Assisted Circulatory Support, and industry partners gathered to discuss relevant issues regarding the current regulatory environment assessing ventricular assist devices. The goal of the meeting was to explore innovative ways to foster the introduction of technologically advanced, safe, and effective ventricular assist devices. The following summary reflects opinions and conclusions endorsed by The Society of Thoracic Surgeons, American Association for Thoracic Surgery, American Heart Association, Heart Failure Society of America, International Society for Heart and Lung Transplantation, and Interagency Registry of Mechanically Assisted Circulatory Support.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: The Annals of Thoracic Surgery - Volume 94, Issue 6, December 2012, Pages 2147-2158
Journal: The Annals of Thoracic Surgery - Volume 94, Issue 6, December 2012, Pages 2147-2158
نویسندگان
Michael A. MD, Francis D. MD, PhD, Wendy Gattis PharmD, Douglas L. MD, Mariell MD, Robert MD, Mark S. MD, Timothy PhD, Lynne MD, Keith D. MD, Leslie MD, David PhD, Clyde MD, Joseph MD, Jeffrey MD, Randall C. MD, MPH, Bartley MD, Steven MD, Michael MD,